Nyree Nava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nyree Nava has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Juan Pinilla
CES University School of Medicine, Medellín, Colombia
2 shared publications - Miguel Angel Samaniego Laguna
Universidad Autonoma Metropolitana, Mexico City, Mexico
2 shared publications - Sebastian Jaramillo
Universidad Austral Pilar Argentina
2 shared publications - Brijesh Baral
Birat Medical College and Teaching Hospital
1 shared publication - Fabio R. Farias
Federal University of Parana Curitiba Brazil
1 shared publication - Ivo Queiroz
University of Wisconsin-Madison , Madison , Wisconsin, USA , wisc.edu
1 shared publication
Latest Publications
- 24 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2675-2685
MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis
Background: The optimal management of secondary mitral regurgitation (MR) remains uncertain, with surgical and percutaneous approaches offering alternative treatment strategies. Aim: To compare percutaneous repair with mitral transcatheter edge‐to‐edge repair (M‐TEER) using MitraClip and surgical intervention in patients with secondary MR. Methods: We systematically searched PubMed, Embase, and Cochrane for studies comparing M‐TEER using MitraClip with surgery in secondary MR, reporting outcomes of interest. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random‐effects model in R software. Heterogeneity was assessed with I² statistics. Results: A total of 11 studies (two randomized controlled trials and nine observational studies) comprising 1605 patients were included. The mean age was 69 years. Among them, 906 (57.7%) underwent MitraClip. Mean follow‐up was 24.7 months (minimum: 6 months). The rate of MR grade ≤ 2+ at follow‐up was lower in the MitraClip group compared to surgery (RR: 0.86, 95% CI: 0.78 to 0.95, p < 0.01). No significant differences were observed in all‐cause mortality (RR: 1.18, 95% CI: 0.93 to 1.49, p = 0.16), cardiovascular mortality (RR: 1.42, 95% CI: 0.54 to 3.68, p = 0.47), heart failure hospitalizations (RR: 1.55, 95% CI: 0.79 to 3.04, p = 0.20), or NYHA class I/II at follow‐up (RR: 0.92, 95% CI: 0.83 to 1.01, p = 0.08). Conclusion: Although patients undergoing MitraClip exhibited a lower rate of residual MR ≤ 2+ at follow‐up compared to those treated surgically, this did not translate into higher rates of clinical outcomes, including all‐cause mortality, cardiovascular mortality, heart failure hospitalizations, or impaired functional status (NYHA classification).
- 24 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2675-2685
MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis
Background: The optimal management of secondary mitral regurgitation (MR) remains uncertain, with surgical and percutaneous approaches offering alternative treatment strategies. Aim: To compare percutaneous repair with mitral transcatheter edge‐to‐edge repair (M‐TEER) using MitraClip and surgical intervention in patients with secondary MR. Methods: We systematically searched PubMed, Embase, and Cochrane for studies comparing M‐TEER using MitraClip with surgery in secondary MR, reporting outcomes of interest. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random‐effects model in R software. Heterogeneity was assessed with I² statistics. Results: A total of 11 studies (two randomized controlled trials and nine observational studies) comprising 1605 patients were included. The mean age was 69 years. Among them, 906 (57.7%) underwent MitraClip. Mean follow‐up was 24.7 months (minimum: 6 months). The rate of MR grade ≤ 2+ at follow‐up was lower in the MitraClip group compared to surgery (RR: 0.86, 95% CI: 0.78 to 0.95, p < 0.01). No significant differences were observed in all‐cause mortality (RR: 1.18, 95% CI: 0.93 to 1.49, p = 0.16), cardiovascular mortality (RR: 1.42, 95% CI: 0.54 to 3.68, p = 0.47), heart failure hospitalizations (RR: 1.55, 95% CI: 0.79 to 3.04, p = 0.20), or NYHA class I/II at follow‐up (RR: 0.92, 95% CI: 0.83 to 1.01, p = 0.08). Conclusion: Although patients undergoing MitraClip exhibited a lower rate of residual MR ≤ 2+ at follow‐up compared to those treated surgically, this did not translate into higher rates of clinical outcomes, including all‐cause mortality, cardiovascular mortality, heart failure hospitalizations, or impaired functional status (NYHA classification).
- 18 August 2025
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (6) , e574-e576
Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
- 18 August 2025
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (6) , e574-e576
Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis